Ключевые слова:
острый коронарный синдром, эндотелин-1, эндотелиальная дисфункция, факторы риска.Библиографические ссылки
Hickey KA, Rubanyi GM, Paul RJ, et al. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Amer J Physiology 1985; 248: 550-6
Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 2008; 86: 485-98.
Л.И., Ольбинская, Ю.И. Найманн Ю.И. Эндотелиновая агрессия в патогенезе хронической сердечной недостаточности и подходы к ее терапевтической коррекции. Тер архив.- 2005; 9: 88-93)
Capone C, Faraco G, Coleman C, et al. Endothelin-1-dependent neurovascular dysfunction in chronic intermittent hypoxia. Hypertension. 2012; 60: 106-13
Application of the New York State PTCA mortality model in patients undergoing stent implantation / D.R. J. Holmes, P.B. Berger, K.N. Garratt et al. // Circulation. – 2000. – Vol. 102. – P. 517–522
Application of the New York State PTCA mortality model in patients undergoing stent implantation / D.R. J. Holmes, P.B. Berger, K.N. Garratt et al. // Circulation. – 2000. – Vol. 102. – P. 517–522
Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study / G.S. Mintz, J.J. Popma, A.D. Pichard et al. // Circulation. – 1996. – Vol. 94. – P. 35–43
Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874.
Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999;340(2):115–126.
Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART study). Lancet. 2004;364(9438):937–952.
Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality (PURE study). Lancet. 2020;395(10226):795–808.
Schiffrin EL. Vascular remodeling in hypertension. Hypertension. 2012;59(2):367–374.
Whooley MA, Wong JM. Depression and cardiovascular disorders. Annu Rev Clin Psychol. 2013;9:327–354.
Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome. Circulation. 2014;129(12):1350–1369.
Barton M, Yanagisawa M. Endothelin: 30 years from discovery to therapy. Hypertension. 2019;74(6):1232–1265.
Lerman A, Holmes DR, Bell MR, et al. Endothelin in coronary endothelial dysfunction. Circulation. 1995;92(9):2426–2431.
Matsumoto T, Miyauchi T, Sakai S, et al. Increased plasma endothelin-1 levels in acute myocardial infarction. Am Heart J. 1997;133(6):615–620.
Reriani MK, Lerman LO, Lerman A. Endothelial function and cardiovascular risk. Biomark Med. 2010;4(3):351–360.
Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. 2019;16(8):491–502.
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367.
Schiffrin EL. Endothelin and endothelial dysfunction. Hypertension. 2001;37(2):581–587.
Virdis A, Ghiadoni L, Giannarelli C, Taddei S. Endothelial dysfunction and vascular disease. Maturitas. 2010;67(1):20–24.
Csige I, Ujvárosy D, Szabó Z, et al. The impact of obesity on the cardiovascular system. J Diabetes Res. 2018; 2018:3407306.